Got­tlieb, Marks de­tail plans to ad­vance de­vel­op­ment of cell and gene ther­a­pies

FDA Com­mis­sion­er Scott Got­tlieb and Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search (CBER) Di­rec­tor Pe­ter Marks on Tues­day de­tailed plans for the agency to keep pace with an ex­pect­ed in­flux of ap­pli­ca­tions for cell and gene ther­a­pies over the com­ing years.

“The FDA is wit­ness­ing a surge of cell and gene ther­a­py prod­ucts en­ter­ing ear­ly de­vel­op­ment, ev­i­denced by a large up­swing in the num­ber of in­ves­ti­ga­tion­al new drug (IND) ap­pli­ca­tions,” Got­tlieb and Marks say.

Scott Got­tlieb

By 2020, Got­tlieb and Marks say they ex­pect to be re­ceiv­ing up­wards of 200 INDs for cell and gene ther­a­pies each year, adding to the 800 ac­tive INDs for such prod­ucts al­ready filed with the agency. By 2025, they pre­dict the agency will be ap­prov­ing be­tween 10 and 20 cell and gene ther­a­py prod­ucts an­nu­al­ly.

The two FDA lead­ers draw a com­par­i­son be­tween the cur­rent land­scape for cell and gene ther­a­pies to the pro­lif­er­a­tion of an­ti­body drugs in the late 1990s once plat­forms for cre­at­ing an­ti­bod­ies that wouldn’t be re­ject­ed by a pa­tient’s im­mune sys­tem were wide­ly avail­able.

“In this case, it was the ad­vent of safe and ef­fec­tive vec­tors for the de­liv­ery of gene ther­a­py prod­ucts, such as the adop­tion of ade­no-as­so­ci­at­ed virus (AAV) vec­tors,” Got­tlieb and Marks say.

Pe­ter Marks

To pro­mote the con­tin­ued de­vel­op­ment of new cell and gene ther­a­pies, Got­tlieb and Marks say that the FDA will take a num­ber of steps, in­clud­ing adding as many as 50 ad­di­tion­al re­view­ers to its staff, lever­ag­ing ex­pe­dit­ed path­ways, is­su­ing new guid­ance and tak­ing en­force­ment ac­tion against clin­ics that fail to com­ply with FDA reg­u­la­tions.

Ac­cord­ing to Got­tlieb and Marks, ac­cel­er­at­ed ap­proval is par­tic­u­lar­ly rel­e­vant for gene ther­a­pies as the agency can man­date post­mar­ket stud­ies to mea­sure the dura­bil­i­ty of the treat­ment and long-term safe­ty is­sues that would be dif­fi­cult to ad­dress in the pre­mar­ket set­ting.

As for new guid­ance, Got­tlieb and Marks say the agency will de­vel­op a se­ries of clin­i­cal guid­ance doc­u­ments for dif­fer­ent ar­eas of prod­uct de­vel­op­ment, such as gene ther­a­pies for in­her­it­ed blood dis­or­ders and neu­rode­gen­er­a­tive dis­eases.

In some cas­es, Got­tlieb and Marks say that a more tra­di­tion­al ap­proach to drug de­vel­op­ment may be war­rant­ed for cer­tain gene ther­a­pies, such as those in­tend­ed to ad­dress the symp­toms of a neu­rode­gen­er­a­tive dis­ease or tar­get an “ex­pres­sion of a pro­tein or en­zyme be­lieved to play a role in the ad­vance of the dis­ease.”

In an­oth­er planned guid­ance, Got­tlieb and Marks say the agency will tack­le the man­u­fac­tur­ing com­plex­i­ties of cell-based gene ther­a­pies, such as chimeric anti­gen re­cep­tor (CAR) T-cell ther­a­pies, in a fu­ture guid­ance.

“The guid­ance that we in­tend to is­sue will pro­mote a bet­ter un­der­stand­ing of the crit­i­cal qual­i­ty at­trib­ut­es and oth­er fac­tors re­lat­ed to prod­uct man­u­fac­tur­ing,” they write, adding that one of their goals will be to min­i­mize the need for bridg­ing stud­ies for mi­nor man­u­fac­tur­ing changes for cell ther­a­pies.

The two al­so say that the FDA will is­sue a guid­ance lat­er this year out­lin­ing how re­searchers can “pool their clin­i­cal da­ta af­ter fol­low­ing a com­mon man­u­fac­tur­ing pro­to­col, and there­by de­vel­op a more ro­bust da­ta set for pur­pos­es of gain­ing a [Bi­o­log­ics Li­cense Ap­pli­ca­tion] BLA.”


First pub­lished here. Reg­u­la­to­ry Fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion.

Elias Zerhouni (Photo by Vincent Isore/IP3/Getty Images)

Elias Zer­houni dis­cuss­es ‘am­a­teur hour’ in DC, the de­struc­tion of in­fec­tious dis­ease R&D and how we need to prep for the next time

Elias Zerhouni favors blunt talk, and in a recent discussion with NPR, the ex-Sanofi R&D and ex-NIH chief had some tough points to make regarding the pandemic response.

Rather than interpret them, I thought it would be best to provide snippets straight from the interview.

On the Trump administration response:

It was basically amateur hour. There is no central concept of operations for preparedness, for pandemics, period. This administration doesn’t want to or has no concept of what it takes to protect the American people and the world because it is codependent. You can’t close your borders and say, “OK, we’re going to be safe.” You’re not going to be able to do that in this world. So it’s a lack of vision, basically just a lack of understanding, of what it takes to protect the American people.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

George Yancopoulos (Regeneron)

Re­gen­eron co-founder George Yan­copou­los of­fers a com­bat­ive de­fense of the po­lice at a high school com­mence­ment. It didn’t go well

Typically, the commencement speech at Yorktown Central School District in Westchester — like most high schools — is an opportunity to encourage students to face the future with confidence and hope. Regeneron president and co-founder George Yancopoulos, though, went a different route.

In a fiery speech, the outspoken billionaire defended the police against the “prejudice and bias against law enforcement” that has erupted around the country in street protests from coast to coast. And for many who attended the commencement, Yancopoulos struck the wrong note at the wrong time, especially when he combatively challenged someone for interrupting his speech with a honk for “another act of cowardness.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

An ex­pe­ri­enced biotech is stitched to­geth­er from transpa­cif­ic parts, with 265 staffers and a fo­cus on ‘new bi­ol­o­gy’

Over the past few years, different teams at a pair of US-based biotechs and in labs in Japan have labored to piece together a group of cancer drug programs, sharing a single corporate umbrella with research colleagues in Japan. But now their far-flung operations have been knit together into a single unit, creating a pipeline with 10 cancer drug development programs — going from early-stage right into Phase III — and a host of discovery projects managed by a collective staff of some 265 people.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

New stan­dard of care? FDA hands Pfiz­er, Mer­ck KGaA an OK for Baven­cio in blad­der can­cer

The breakthrough therapy designation Pfizer and Merck KGaA notched for Bavencio in bladder cancer has quickly paved way for a full approval.

The PD-L1 drug is now sanctioned as a first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma, applicable in cases where cancer hasn’t progressed after platinum-containing chemotherapy.

Petros Grivas, the principal investigator of the supporting Phase III JAVELIN Bladder 100, called the approval “one of the most significant advances in the treatment paradigm in this setting in 30 years.”

Sec­ond death trig­gers hold on Astel­las' $3B gene ther­a­py biotech's lead pro­gram, rais­ing fresh con­cerns about AAV

Seven months after Astellas shelled out $3 billion to acquire the gene therapy player Audentes, the biotech company’s lead program has been put on hold following the death of 2 patients taking a high dose of their treatment. And there was another serious adverse event recorded in the study as well, with a total of 3 “older” patients in the study affected.

The incidents are derailing plans to file for a near-term approval, which had been expected right about now.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

On a roll, Mer­ck blazes through a new seg­ment of the bio­mark­er trail

Merck has notched an approval for using Keytruda to treat a biomarker-based subset of first-line colorectal cancer patients with unresectable or metastatic tumors, as the pharma giant continues to find new niches for its blockbuster PD-1 star.

The OK is significant in a number of ways. Not only does it build on an accelerated approval for all tumors characterized as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR); it also marks the first single treatment for colorectal cancer that doesn’t contain chemotherapy.

Pfiz­er shares surge on pos­i­tive im­pact of their mR­NA Covid-19 vac­cine — part­nered with BioN­Tech — in an ear­ly-stage study

Pfizer and their partners at the mRNA specialist BioNTech have published the first glimpse of biomarker data from an early-stage study spotlighting the “robust immunogenicity” triggered by their Covid-19 vaccine, which is one of the leaders in the race to vanquish the global pandemic.

Researchers selected 45 healthy volunteers 18-55 years of age for the study. They were randomized to receive 2 doses, separated by 21 days, of 10 µg, 30 µg, or 100 µg of BNT162b1, “a lipid nanoparticle-formulated, nucleoside-modified, mRNA vaccine that encodes trimerized SARS-CoV-2 spike glycoprotein RBD.” Their responses were compared against the effect of a natural, presumably protective defense offered by a regular infection.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi CEO (Getty Images)

Sanofi preps an­oth­er round of lay­offs as new ex­ecs look to slim down the glob­al phar­ma in an on­go­ing re­or­ga­ni­za­tion — re­port

Sanofi is reportedly once again sharpening up the budget axe as the pharma giant prepares to chop more jobs.

Reuters reports this morning that Sanofi has its sights set on cutting 1,680 jobs in Europe, where the unions have been combating rounds of cutbacks at the Paris-based player. Sanofi itself hasn’t said anything about these cuts, as the company looks to discuss a 3-year plan with staff representatives.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: Vac­cines will need to beat place­bo by 50% to qual­i­fy for FDA OK; UK tri­al drops Kale­tra

The FDA will set the bar for approving a Covid-19 vaccine at 50% efficacy, the Wall Street Journal reported, meaning any successful candidate will have to reduce the risk of coronavirus disease by at least half compared to placebo.

That requirement is part of guidance that the agency is set to release later today, laying out detailed criteria for vaccine developers — some of whom are eyeing an OK by the end of the year, in line with expectations at Operation Warp Speed.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.